Abstract
The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was injected intraperitoneally in mice and caused an acute inhibition (of over 60%) of gastrointestinal motility, which was measured by the transit of charcoal. This inhibition was not related to conversion of MPTP to MPP+. Administration of the β-adrenergic blocker propranolol significantly reduced, but did not completely block, the effect of MPTP. The dopaminergic blocker haloperidol also partly reversed the effects of MPTP. When these blockers were administered together, the action of MPTP was fully blocked. The results indicate that the toxin acted by releasing catecholamines (presumably norepinephrine and dopamine), thereby inhibiting motility.
Similar content being viewed by others
References
Kopin IJ, Markey SP: MPTP toxicity: Implications for research in Parkinson's disease. Annu Rev Neurosci 11:81–96, 1988
Gerlach M, Riederer P, Przuntek H, Youdim MB: MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 208:273–286, 1991
Fuller RW, Hemrick-Luecke SK: Depletion of norepinephrine in mouse heart by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), mimicked by 1-methyl-4-phenylpyridinium and not blocked by deprenyl. Life Sci 39:1645–1650, 1986
Ambrosio S, Blesa R, Mintenig GM, Palacios-Araus L, Mahy M, Gual A: Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines in heart, adrenal gland, retina an caudate nucleus of the cat. Toxicol Lett 44:1–6, 1988
Szabo S, Brown A, Pihan G, Dali H, Neumeyer L: Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Proc Soc Exp Biol Med 180:567–571, 1985
Alkadhi KA, Hogan YH: Effects of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) on ganglionic transmission. J Auton Pharmacol 12:15–23, 1992
Eaker EY, Bixler GB, Dunn AJ, Moreshead WV, Mathias JR: Chronic alterations in jejunal myoelectric activity due to MPTP. Am J Physiol 253:G809-G815, 1987
Mangla JC, Pihan G, Brown HA, Rattan S, Szabo S: Effect of duodenal ulcerogens cysteamine, mepirizole, and MPTP on duodenal myoelectric activity in rats. Dig Dis Sci 34:537–542, 1989
Hanani M: Rapid effects of MPTP in the mouse colon. Eur J Pharmacol 175:273–277, 1990
Wong CL: The effect of nalbuphine on gastrointestinal transit in mice, Eur J Pharmacol 135:219–223, 1986
Daniel EE: Pharmacology of adrenergic, cholinergic, and drugs acting on other receptors in gastrointestinal muscle,In Handbook of Experimental Pharmcology, Vol 59/2, Mediators and Drugs in Gastrointestinal Motility, II. G Bertaccini (ed). New York, Springer, 1982, pp 249–322
Keshavarzian A, Wibowo A, Gordon JH, Fields JZ: MPTP-induced duodenal ulcers in rat. Prevention by reuptake blockers for serotonin and norepinephrine, but not dopamine. Gastroenterology 98:554–560, 1990
Wilson SP, Beeler JF: Catecholamine depletion and accumulation of effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenyl-pyridinium (MPP+) in adrenal medullary chromaffin cells. Neurochem Int 13:333–343, 1988
Author information
Authors and Affiliations
Additional information
Supported by a grant from the Joint Research Fund of the Hebrew University and Hadassah.
Rights and permissions
About this article
Cite this article
Haskel, Y., Hanani, M. Inhibition of gastrointestinal motility by MPTP via adrenergic and dopaminergic mechanisms. Digest Dis Sci 39, 2364–2367 (1994). https://doi.org/10.1007/BF02087652
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02087652